Formulation Development and Evaluation of Colon Targetted Matrix Tablets of Gliclazide

Gliclazide was formulated as a hydrophobic matrix sustained release tablet employing HPMC using different grade materials and the sustained release behavior of the fabricated tablet was investigated. Sustained release matrix tablets containing 60 mg Gliclazide were developed using different grade of HPMC combinations with coated enteric coating polymers like Eudragit L100 and S100 were used as coating materials. The tablets were prepared by wet granulation technique. The physical properties were found to be satisfactory for all the formulae.The formulation was optimized on the basis of acceptable tablet properties and in vitro drug release. The resulting formulation produced monolithic tablets with optimum hardness,   uniform thickness, consistent weight uniformity and low friability. Statistically significant differences were found among the drug release profile from different HPMC combination matrices. The in vitro study revealed that combining of HPMC (Methocel K100LV-CR Premium (IF10805), HPMC K4M and use of Dibasic Calcium Phosphate as filler sustained the action more than 12 h. The developed sustained release matrix tablet of improved efficacy can perform therapeutically better than a conventional tablet

Effect of honey on carbamazepine kinetics in rabbits

560-563<span style="font-size:14.0pt;line-height: 115%;font-family:" times="" new="" roman";mso-fareast-font-family:"times="" roman";="" color:black;mso-ansi-language:en-in;mso-fareast-language:en-in;mso-bidi-language:="" hi"="" lang="EN-IN">The study was undertaken to determine the effect of honey on carbamazepine kinetics in rabbits. The study was done on three occasions in each animal. Study 1 was carried out after single dose administration of carbamzepine (80 mg/kg, po along with saline (2.34 ml/kg, po. After a wash out period of one week, the second study was carried out by coadministration of carbamazepine with honey (2.34ml/kg, po). After this, the animals continued to receive honey (2.34 ml/kg ,po), once daily, for 7 days. On the eighth day of honey treatment, the carbamazepine kinetics was studied again. Pharmacokinetic analysis revealed that single as well as multiple dose honey treatment showed a significant decrease in area under the plasma time concentration curve (AUC) when compared with saline treated control. A significant increase in the clearance (CL/F) rate of carbamazepine was observed only after multiple dose honey treatment. Both single and multiple dose honey treatment did not show any significant effect on other pharmacokinetic parameters like tl/2, Cmax, Tmax and Vd when compared with saline treated group. Data thus obtained suggested that honey decreases the bioavailability of carbamazepine.</span

Influence of honey on orally and intravenously administered diltiazem kinetics in rabbits

1164-1168<span style="font-size: 15.0pt;mso-bidi-font-size:9.0pt;font-family:" times="" new="" roman","serif";="" color:black"="">Effect of honey on plasma concentration of diltiazem after oral and intravenous administration in rabbits, has been studied. For oral study, single dose of diltiazem (5mg/kg, po) along with saline was administered to New Zealand white rabbits (n=8). Blood samples were collected at 0, 0.25, 0.5, 0.75, 1, 1.5,2,3,4,6 and 8 hr after drug administration from marginal ear vein. After a washout period of one week, diltiazem was administered with honey (2.34ml/kg; po) and the blood samples were collected as above. To the same animals honey (2.34 ml/kg; po) was continued once daily for 7 days. On 8thday, honey and diltiazem were administered simultaneously and blood samples were collected at similar time intervals as mentioned above. For intravenous study the pharmacokinetic was done in each animal on two occasions. The first study was done after single dose administration of diltiazem (5ml/kg; iv) along with saline (2.34ml/kg; po). Blood samples were collected at 0, 0.083, 0.25, 0.5, 0.75, 1, 1.5,2, 3, 4 and 6 hr after iv diltiazem administration. The same animals were treated with honey (2.34 ml/kg; po) for seven days. On day 8, the second study was carried out with single dose iv administration of diltiazem along with honey (2.34ml/kg; po) and blood samples were collected. In the oral study, single dose administration of honey decreased the AUC and Cmax of diltiazem associated with significant increase in clearance and volume of distribution when compared to saline treated group. After one week administration of honey, diltiazem kinetic data showed further reduction in AUC and Cmax and increase in clearance and volume of distribution. In the iv study also, multiple dose administration of honey significantly reduced the AUC and increased the clearance value of diltiazem. The results suggest that honey may decrease the plasma concentration of diltiazem after its oral or iv administration in rabbits. </span